Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mantle Cell Lymphoma (MCL) is a B-cell neoplasm with CCND1 [t(11;14)(q13;q32), cyclin D1] translocation.
|
31786879 |
2020 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
|
31688139 |
2020 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by CCND1/IGH rearrangement.
|
31433838 |
2020 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation resulting in overexpression of cyclin D1.
|
30538135 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1.
|
30967367 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is characterized by the translocation t(11;14) (q13;q32), resulting in the overexpression of cyclin-D1.
|
30857748 |
2019 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle.
|
31120355 |
2019 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-D1 negative MCL, in situ MCL neoplasia, and impact of the karyotype on prognosis are distinguished.
|
30963600 |
2019 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we reviewed 798 cases of MCL and identified 103 (13%) that were CD23+ by flow cytometry, all of which were positive for cyclin D1 and/or associated with CCND1/IGH.
|
31054894 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that expression of cyclin D1 in MCL is not controlled by ENGL2/PHD1-FOXO3A pathway and that chelation- and 2-oxoglutarate competition-mediated down-regulation of cyclin D1 in MCL cells is driven by yet unknown mechanism involving iron- and 2-oxoglutarate-dependent dioxygenases other than PHD1.
|
31517438 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is a comparatively rare non-Hodgkin's lymphoma characterised by overexpression of cyclin D1.
|
30465121 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that ectopic expression of CCND1 in multiple human MCL cell lines resulted in increased SOX11 transcription, which correlated with increased acetylated histones H3K9 and H3K14 (H3K9/14Ac).
|
30530749 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of cyclin D1 is a hallmark of MCL.
|
31229158 |
2019 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we report 3 cases of nodal PMBL, 2 of them without mediastinal mass, and expression of cyclin D1 due to copy number gains of CCND1 gene, a diagnostic pitfall with mantle cell lymphoma and DLBCL, not otherwise specified.
|
30211726 |
2019 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When cyclin D1 was overexpressed by the Eμ-cyclin D1 transgene, ATA B cells progressed to further diffused lymphoma in aged mice, including in various lymph nodes with accumulation of IgM<sup>hi</sup>IgD<sup>lo</sup>CD5<sup>+</sup>CD23<sup>-</sup>CD43<sup>+</sup> cells, resembling aggressive human mantle cell lymphoma.
|
29898964 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diagnosis of MCL relies on the identification of the t(11;14) translocation by FISH or the consequently aberrant expression of cyclin D1 by immunohistochemistry.
|
30132080 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is currently unclear how cyclin D1 overexpression and aberrant CDK4 activity affect NOXA stabilization and treatment efficacy of UPS inhibitors in MCL.
|
30180865 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
|
29273915 |
2018 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified recurrent mutations in genes that are well known to be functionally relevant in MCL, including ATM (37.5%), TP53 (31.3%), WHSC1 (31.3%), CCND1 (18.8%), NOTCH2 (6.3%), and CDKN2A (6.3%).
|
29755111 |
2018 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most commonly used molecular markers for measuring MRD in MCL are: t(11;14)(q13;p32) translocation or CCND1 expression and IGH rearrangement.
|
29520657 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression and constitutive activation of CYCLIN D1 and Casein Kinase 2 are common features of many hematologic malignancies, including mantle cell lymphoma (MCL) and leukemias such as T-cell acute lymphoblastic leukemia (T-ALL).
|
30701029 |
2018 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 and SOX11 only stain the central portion that represents MCL and LEF-1 stains the periphery that represents CLL/SLL.
|
28109040 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases.
|
29990311 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1.
|
28140709 |
2017 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is a B-cell hemopathy characterized by the t(11;14) translocation and the aberrant overexpression of cyclin D1.
|
28797244 |
2017 |